Carboplatin

别名: NSC 241240, JM-8, CBDCA 中文名称：卡铂

铂类药物不建议使用DMSO溶解，易失活！

目录号：S1215 Purity: 99.98%

Carboplatin是 CDDP 的衍生物，是一种 DNA 合成抑制剂，在 A2780、SKOV-3、IGROV-1 和 HX62 细胞中可与 DNA 结合，抑制复制和转录，诱导细胞死亡并干扰细胞的修复机制发挥作用。它诱导 DNA 链间交联和 DNA-蛋白质交联的形成。在溶液中不稳定，请现配现用！铂类药物不建议用DMSO溶解，易失活！

Carboplatin Chemical Structure

CAS: 41575-94-4

规格	价格	库存
50mg	630.25	现货
200mg	1367.43	现货
1g	4013.1	现货
10g	22686.3	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.98%

99.98

Carboplatin相关产品

相关产品	Puromycin 2HCl Staurosporine (STS) Oligomycin A Geldanamycin Honokiol Geneticin (G418 Sulfate) Nigericin sodium salt STZ (Streptozotocin) Cephalomannine Sodium Monensin (NSC 343257) 10-Deacetylbaccatin-III Pirarubicin Hygromycin B Roxithromycin	点击展开
相关化合物库	FDA药物库天然产物库凋亡分子化合物库 DNA损伤/ DNA修复化合物库细胞周期化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息
H460	Growth Inhibition Assay	7.9 μM	24 h	shows a radiosensitizing effect to X-rays	25599995
A549/CDDP	Growth Inhibition Assay	0.2-4000 μM	72 h	IC50=240 ± 45.7 μM	25625243
A549	Growth Inhibition Assay	0.2-4000 μM	72 h	IC50=126 ± 5.0 μM	25625243
A-549	Fuction Assay	0.5 μM	48 h	inhibits of cell migration	25755690
A-549	Fuction Assay	0.5 μM	48 h	shows aberrant microtubule disruption	25755690
A-549	Apoptosis Assay	0.5 μM	48 h	shows early apoptosis features including blebbing and chromatin condensation	25755690
A-549	Growth Inhibition Assay	0.5 μM	24 h	inhibits cell growth significantly	25755690
MCF7	Growth Inhibition Assay	20 μM	72 h	induces cell death of HP1β-depleted MCF7 cells	25769025
T47D	Growth Inhibition Assay	0-220 μg/ml	72 h	IC50 = 48.9 μM	25837691
MDA-MB-231	Growth Inhibition Assay	0-220 μg/ml	72 h	IC50 = 86 μM	25837691
H1975	Growth Inhibition Assay	25 μM	24 h	inhibits cell growth	25917317
A549	Growth Inhibition Assay	25 μM	24 h	inhibits cell growth	25917317
H1975	Fuction Assay	0/25/50 μM	24 h	upregulates miR-218 expression	25917317
A549	Fuction Assay	0/25/50 μM	24 h	upregulates miR-218 expression	25917317
H1975	Fuction Assay	0/25/50 μM	24 h	downregulates miR-205 expression	25917317
A549	Fuction Assay	0/25/50 μM	24 h	downregulates miR-205 expression	25917317
SKOV3	Apoptosis Assay	2 μg/ml	48 h	induces apoptosis	26125273
SKOV3	Growth Inhibition Assay	0-4 μg/ml	24/48/72 h	inhibits cell viability dose and time dependently	26125273
SKOV3	Growth Inhibition Assay	60 mg/ml	1-5 d	inhibits cell viability time dependently	26137043
Tca8113/PYM	Growth Inhibition Assay	2-25 μM	72 h	inhibits cell viability dose dependently	26137105
Tca8113/CBP	Growth Inhibition Assay	2-25 μM	72 h	inhibits cell viability dose dependently	26137105
Tca8113/ut	Growth Inhibition Assay	2-25 μM	72 h	inhibits cell viability dose dependently	26137105
PC9	Apoptosis Assay	100 µM	72 h	induces apoptosis	24618809
A549	Apoptosis Assay	100 µM	72 h	induces apoptosis	24618809
IMR-32	Fuction Assay	10 μM		induces apoptosis significantly combined with GSK2830371	25658463
CHP-134	Fuction Assay	10 μM		induces apoptosis significantly combined with GSK2830371	25658463
IMR-32	Growth Inhibition Assay	1 μM		inhibits significant cell growth combined with GSK2830371	25658463
CHP-134	Growth Inhibition Assay	1 μM		inhibits significant cell growth combined with GSK2830371	25658463
OSA	Clonogenic Assay	2.5/5 μM		results in lower colony formation as compared to either BMI1 siRNA treatment	26110620
HeLa	Growth Inhibition Assay	5-80 μM		inhibits cell growth dose dependently	25109360
MCF-7	Growth Inhibition Assay	5-80 μM		inhibits cell growth dose dependently	25109360
MDA-MB-231	Growth Inhibition Assay	5-80 μM		inhibits cell growth dose dependently	25109360
OVCAR-3	Growth Inhibition Assay		72 h	IC50=32.6 μM	25520132
SW626	Growth Inhibition Assay		72 h	IC50=97.0 μM	25520132
A2780	Growth Inhibition Assay		72 h	IC50=145.7 μM	25520132
3AO	Growth Inhibition Assay		72 h	IC50=63.4 μM	25520132
OVCAR-8	Growth Inhibition Assay		72 h	IC50=96.0 μM	25520132
ES-2	Growth Inhibition Assay		72 h	IC50=14.6 μM	25520132
SK-OV-3	Growth Inhibition Assay		72 h	IC50=104.8 μM	25520132
RGE	Growth Inhibition Assay		72 h	IC80=63 ± 7.4 μM	25565603
NRK-52E	Growth Inhibition Assay		72 h	IC80=179 ± 9.5 μM	25565603
RGE	Growth Inhibition Assay		72 h	IC50=22 ± 7.4 μM	25565603
NRK-52E	Growth Inhibition Assay		72 h	IC50=100 ± 12.9 μM	25565603
H460	Growth Inhibition Assay		24 h	IC50=7.9 μM	25599995
CaOV3	Growth Inhibition Assay		72 h	IC50=86.1 μM	25068849
OVCAR-3	Growth Inhibition Assay		72 h	IC50=179.5 μM	25068849
OVCAR-5	Growth Inhibition Assay		72 h	IC50=75.7 μM	25068849
SKOV-3	Growth Inhibition Assay		72 h	IC50=504 μM	25068849
OVCAR-4	Growth Inhibition Assay		72 h	IC50=290.6 μM	25068849
OVCAR-8	Growth Inhibition Assay		72 h	IC50=690.2 μM	25068849
MA148	Growth Inhibition Assay		24 h	IC50=83.6 ± 1.4 μg/ml	24831091
A549	Growth Inhibition Assay		24 h	IC50=776.0 ± 1.9 μg/ml	24831091
MDA-MB-231	Growth Inhibition Assay		24 h	IC50=748.0 ± 1.1 μg/ml	24831091
NCI-ADR/RES	Growth Inhibition Assay		24 h	IC50=1753.0 ± 4.4 μg/ml	24831091
MA148	Growth Inhibition Assay		48 h	IC50=28.1 ± 1.0 μg/ml	24831091
A549	Growth Inhibition Assay		48 h	IC50=118.0 ± 1.2 μg/ml	24831091
MDA-MB-231	Growth Inhibition Assay		48 h	IC50=183.0 ± 1.2 μg/ml	24831091
NCI-ADR/RES	Growth Inhibition Assay		48 h	IC50=193.0 ± 1.9 μg/ml	24831091
MA148	Growth Inhibition Assay		72 h	IC50=13.7 ± 1.2 μg/ml	24831091
A549	Growth Inhibition Assay		72 h	IC50=64.3 ± 1.1 μg/ml	24831091
MDA-MB-231	Growth Inhibition Assay		72 h	IC50=99.5 ± 1.1 μg/ml	24831091
NCI-ADR/RES	Growth Inhibition Assay		72 h	IC50=37.4 ± 1.7 μg/ml	24831091
A549	Growth Inhibition Assay		72 h	IC50=152.409 μM	24721323
NCI-H157	Growth Inhibition Assay		72 h	IC50=89.977 μM	24721323
PC9	Growth Inhibition Assay		72 h	GC50=71.6±9.5 µM	24618809
A549	Growth Inhibition Assay		72 h	GC50=136±31.6 µM	24618809
A549	Growth Inhibition Assay		24 h	IC10=1.476 nM	24396437
H1299	Growth Inhibition Assay		24 h	IC10=0.443 nM	24396437
HCC15	Growth Inhibition Assay		24 h	IC10=0.346 nM	24396437
H157	Growth Inhibition Assay		24 h	IC10=0.81 nM	24396437
4T1	Growth Inhibition Assay			IC50=84.62 ± 30.05 μM μM	25277461
A549	Growth Inhibition Assay			IC50=151.56 ± 53.06 μM	25277461
FN-RMG-1-hFUT	Growth Inhibition Assay			IC50=118.8 ± 13.8 mg/L	25726913
RMG-1-hFUT	Growth Inhibition Assay			IC50=58.1 ± 2.4 mg/L	25726913
FN-RMG-1	Growth Inhibition Assay			IC50=40.5 ± 4.2 mg/L μM	25726913
RMG-1	Growth Inhibition Assay			IC50=28.8 ± 3.6 mg/L	25726913
MonoTCC	Growth Inhibition Assay			IC50=5.6 µM	25773167
MegTCC	Growth Inhibition Assay			IC50=4.1 µM	25773167
MCTCC	Growth Inhibition Assay			IC50=2.8 µM	25773167
LCTCC	Growth Inhibition Assay			IC50=3.8 µM	25773167
BALB/3T3	Growth Inhibition Assay			IC50=14.30 ± 6.68 μM	25277461
B16	Growth Inhibition Assay			IC50=64.30 ± 6.81 μM	25277461
DU 145	Growth Inhibition Assay			IC50=35.04 ± 17.54 μM	25277461
FaDu	Growth Inhibition Assay			IC50=45.39 ± 11.50 μM	25277461
HCV-29T	Growth Inhibition Assay			IC50=48.57 ± 22.49 μM	25277461
HL-60	Growth Inhibition Assay			IC50=11.10 ± 4.47 μM	25277461
HT-29	Growth Inhibition Assay			IC50=89.16 ± 18.86 μM	25277461
H146	Growth Inhibition Assay			IC50=49.6±13.1 μM	25124282
H187	Growth Inhibition Assay			IC50=12.7±2.7 μM	25124282
H128	Growth Inhibition Assay			IC50=106.4±9.6 μM	25124282
H69	Growth Inhibition Assay			IC50=76.9±27.8 μM	25124282
H209	Growth Inhibition Assay			IC50=258.1±99.8 μM	25124282
DMS153	Growth Inhibition Assay			IC50=57.8±9.2 μM	25124282
H526	Growth Inhibition Assay			IC50=7.2±1.7 μM	25124282
DMS114	Growth Inhibition Assay			IC50=85.8±12.8 μM	25124282
DMS53	Growth Inhibition Assay			IC50=146.2±36.4 μM	25124282
A2780	Growth Inhibition Assay			IC50=14.0 ± 1.4 μM	24209693
A2780cisR	Growth Inhibition Assay			IC50=48.9 ± 3.9 μM	24209693
A2780ZD0473R	Growth Inhibition Assay			IC50=64.6 ± 3.2 μM	24209693
SKOV-3	Growth Inhibition Assay			IC50=43.4 ± 3.9 μM	24209693
点击查看更多细胞系数据

生物活性

产品描述

特性

不建议使用DMSO溶解。^[6]

靶点

DNA synthesis ^[1]
(A2780, SKOV-3, IGROV-1, HX62 cells)

体外研究(In Vitro)
体外研究活性	Carboplatin作用于一组人类卵巢癌细胞系，包括A2780, SKOV3,和 IGROV-1细胞，抑制细胞增殖,IC50分别为6.1 μM, 12.4 μM 和2.2 μM。^[1]
细胞实验	细胞系	A2780, SKOV3, IGROV-1 和 HX62
	浓度	0 到 200 μM
	孵育时间	72 小时
	方法	MTT实验: 指数生长的A2780, SKOV3, IGROV-1和 HX62卵巢癌细胞接种在96孔板中。加入一系列浓度的Carboplatin，再温育72小时。每组实验按一式三份进行。 Sulforhodamine B (SRB)实验:指数生长的 A2780细胞接种在96孔板中。使用浓度不断增加的17-AAG 和Carboplatin处理细胞96小时。使用浓度不断增加的17-AAG或Carboplatin处理细胞 24小时，研究17-AAG 或 Carboplatin处理序列的效果。选中的第一种药剂处理细胞24小时，确保A2780细胞使用第一种药剂至少处理双倍时间(18-24小时)。使用无菌磷酸盐缓冲液冲洗细胞，然后补充培养基。然后，加入第二种药剂 (第一次24小时未处理细胞的)或培养基，再处理96小时。所有实验按一式三份进行。使用中位数效果分析方法按行之有效的原则分析联合研究的效果。使用内部电子表格计算联用的效果。
实验图片	检测方法	检测指标	实验图片	PMID
	Western blot	pChK-2 / Chk-2 p-p53(S15) / p-p53(S46) / p-p53(S392) / p53 p-p38 / p38 / Cleaved PARP / PARP		30049957
	Immunofluorescence	γH2AX		24348048
	Growth inhibition assay	Cell viability		24348048

体内研究(In Vivo)
体内研究活性	Carboplatin (60 mg/kg，通过腹腔注射)单独作用于A2780移植瘤，具有适度的抗肿瘤效果，处理第6天，相对肿瘤体积为8.4，对照组为11.9, 且处理第6天，T/C为67%。^[1]
动物实验	Animal Models	A2780人类卵巢癌细胞系皮下移植到雌性无胸腺NCr裸鼠(nu/nu)的两侧
	Dosages	≤60 mg/kg （注意：氯化钠溶液与卡铂混合后出现理化、药动学及药效学等方面的配伍禁忌。）
	Administration	腹腔注射

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06393816	Not yet recruiting	Large Cell Neuroendocrine Carcinoma of the Lung	Centre Leon Berard\|Groupe Français de Pneumo-Cancérologie	May 2024	Phase 2
NCT06303713	Not yet recruiting	Prostate Cancer\|Metastatic Prostate Cancer\|Metastatic Castration-resistant Prostate Cancer	Dana-Farber Cancer Institute\|Novartis	May 2024	Phase 1
NCT05846789	Recruiting	Metastatic Breast Cancer\|Triple Negative Breast Cancer\|Estrogen-receptor-low Breast Cancer	Kathy Miller\|Genentech Inc.\|Indiana University	May 2024	Phase 2
NCT06288854	Not yet recruiting	Weight Gain	Rajavithi Hospital	April 3 2024	Not Applicable

参考文献
[1] Banerji U, et al. Cancer Chemother Pharmacol. 2008, 62(5), 769-778. [2] Fiebiger W, et al. Clin Transl Oncol. 2011, 13(1), 43-49. [3] Clark CC, et al. Mol Cancer Ther, 2012, doi: 10.1158/1535-7163.MCT-11-0597. [4] Wang H, et al. Clin Cancer Res. 2004, 10(5), 1633-1644. [5] Liu H, et al. Anticancer Res. 2011, 31(9), 2713-2722. [6] Matthew D Hall, et al. Cancer Res. 2014 Jul 15;74(14):3913-22. [7] Groen HJ, et al. Br J Cancer. 1995 Dec; 72(6): 1406–1411. + 展开

参考文献

+ 展开

化学信息&溶解度

分子量	371.25	分子式	C₆H₁₂N₂O₄Pt
CAS号	41575-94-4	SDF	Download Carboplatin SDF
Smiles	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
储存条件(自收到货起)	2年 4°C（避光）粉末	此产品性质不稳定，需现配现用!建议您购买分装规格，或者在收到货后进行分装。

体外溶解度
批次：

Water : 4.5 mg/mL (12.12 mM)

Ethanol : Insoluble

摩尔浓度计算器

体内溶解度
批次：

现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂

动物体内配方计算器

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

常见问题及建议解决方法

问题 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?

回答：
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):